证券代码：688336 证券简称：三生国健 公告编号：2025-014 三生国健药业（上海）股份有限公司 关于公司 2024 年度日常关联交易执行情况及 2025 年 度日常关联交易预计的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 是否需要提交股东大会审议：是 日常关联交易对上市公司的影响：本次关联交易为公司日常关 联交易，以公司正常经营业务为基础，属于正常商业行为，遵守了自 愿、等价、有偿的原则，定价公平合理，不影响公司的独立性，不存 在损害公司及股东利益的情形，公司不会因该关联交易对关联人产生 依赖。 一、日常关联交易基本情况 （一）日常关联交易履行的审议程序 三生国健药业（上海）股份有限公司（以下简称"公司"或"三 生国健"）于 2025 年 3 月 25 日召开第五届董事会独立董事专门会议 第二次会议，审议通过了《关于公司 2024 年度日常关联交易执行情 1 况及 2025 年度日常关联交易预计的议案》，独立董事认为：公司 2024 年度实施和 2025 年度预计的日常关联交易事项符合公 ...

公司代码：688336 公司简称：三生国健 三生国健药业（上海）股份有限公司 2024 年度内部控制评价报告 三生国健药业（上海）股份有限公司全体股东： 2. 财务报告内部控制评价结论 √有效 □无效 根据公司财务报告内部控制重大缺陷的认定情况，于内部控制评价报告基准日，不存在财务报告内 部控制重大缺陷，董事会认为，公司已按照企业内部控制规范体系和相关规定的要求在所有重大方面保 持了有效的财务报告内部控制。 3. 是否发现非财务报告内部控制重大缺陷 根据《企业内部控制基本规范》及其配套指引的规定和其他内部控制监管要求（以下简称"企业 内部控制规范体系"），结合本公司（以下简称"公司"）内部控制制度和评价办法，在内部控制日常监 督和专项监督的基础上，我们对公司2024年12月31日（内部控制评价报告基准日）的内部控制有效性 进行了评价。 一. 重要声明 按照企业内部控制规范体系的规定，建立健全和有效实施内部控制，评价其有效性，并如实披露 内部控制评价报告是公司董事会的责任。监事会对董事会建立和实施内部控制进行监督。经理层负责 组织领导企业内部控制的日常运行。公司董事会、监事会及董事、监事、高级管理人员保证本报告 ...

非经营性资金占用及其他关联资金往来情况的专项说明 2024年度 三生国健药业（上海）股份有限公司 非经营性资金占用及其他关联资金往来情况的专项说明 安永华明（2025）专字第70072706_A03号 三生国健药业（上海）股份有限公司 三生国健药业（上海）股份有限公司董事会： 我们审计了三生国健药业（上海）股份有限公司的财务报表，包括2024年12月31 日的合并及公司资产负债表，2024年度的合并及公司利润表、股东权益变动表和现金 流量表以及相关财务报表附注，并于2025年3月25日出具了编号为安永华明（2025）审 字第70072706_A01的无保留意见审计报告。 按照《上市公司监管指引第8号——上市公司资金往来、对外担保的监管要求》的 要求，三生国健药业（上海）股份有限公司编制了后附的2024年度非经营性资金占用 及其他关联资金往来情况汇总表（以下简称"汇总表"）。 如实编制和对外披露汇总表，并确保其真实性、合法性、完整性是三生国健药业 （上海）股份有限公司的责任。我们对汇总表所载资料与我们审计三生国健药业（上 海）股份有限公司2024年度财务报表时所复核的会计资料和经审计的财务报表的相关 内容进行了 ...

关于召开 2024 年年度股东大会的通知 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： 一、 召开会议的基本情况 （一） 股东大会类型和届次 2024 年年度股东大会 （二） 股东大会召集人：董事会 证券代码：688336 证券简称：三生国健 公告编号：2025-015 三生国健药业（上海）股份有限公司 股东大会召开日期：2025年4月15日 本次股东大会采用的网络投票系统：上海证券交易所股东大 会网络投票系统 （五） 网络投票的系统、起止日期和投票时间。 网络投票系统：上海证券交易所股东大会网络投票系统 （三） 投票方式：本次股东大会所采用的表决方式是现场投票和网络 投票相结合的方式 （四） 现场会议召开的日期、时间和地点 召开日期时间：2025 年 4 月 15 日 10 点 00 分 召开地点：中国（上海）自由贸易试验区李冰路 399 号公司会议 室 网络投票起止时间：自 2025 年 4 月 15 日 至 2025 年 4 月 15 日 采用上海证券交易所网络投票系统，通过交易系统投票平台的投 票时 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-010 三生国健药业（上海）股份有限公司 第五届监事会第三次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、 监事会会议召开情况 二、监事会会议审议情况 经与会监事认真审议，并以投票表决的方式审议通过了如下决 议： （一）审议通过《关于公司<2024 年度监事会工作报告>的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案需提交公司股东大会审议。 1 （二）审议通过《关于公司<2024 年度财务决算报告>的议案》 表决结果：同意 3 票，反对 0 票，弃权 0 票。 本议案需提交公司股东大会审议。 （三）审议通过《关于公司<2025 年度财务预算报告>的议案》 表决情况：同意 3 票，反对 0 票，弃权 0 票。 三生国健药业（上海）股份有限公司（以下简称"公司"）第五 届监事会第三次会议通知于 2025 年 3 月 14 日以电话、电子邮件、专 人送达等方式发出。会议于 2025 年 3 月 25 日以现场结合通讯方式召 ...

证券代码：688336 证券简称：三生国健 公告编号：2025-009 三生国健药业（上海）股份有限公司 第五届董事会第五次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、董事会会议召开情况 三生国健药业(上海)股份有限公司（以下简称"公司"）第五届 董事会第五次会议通知于 2025 年 3 月 14 日以电话、电子邮件、专人 送达等方式发出。会议于 2025 年 3 月 25 日以现场和通讯结合表决的 方式举行。会议应到董事 7 名，实到董事 7 名。会议由董事长 LOU JING 先生主持，本次会议的召集与召开程序、出席会议人员资格及议事和 表决程序符合《中华人民共和国公司法》（以下简称"《公司法》"） 和《三生国健药业（上海）股份有限公司章程》（以下简称"《公司 章程》"）的有关规定。会议决议合法、有效。 二、董事会会议审议情况 （一）审议通过了《关于公司<2024 年度董事会工作报告>的议 案》 董事会认为董事会工作报告真实地反映了董事会在本报告期的 工作情况。2024 年，公司董事会严格按照《公 ...

Financial Performance - The company reported a significant increase in revenue, achieving a total of 1.2 billion RMB, representing a 25% year-over-year growth[15]. - The company's operating revenue for 2024 reached RMB 119,356.83 million, representing a 17.70% increase compared to RMB 101,403.43 million in 2023[20]. - Net profit attributable to shareholders surged to RMB 70,457.91 million, a remarkable growth of 139.15% from RMB 29,461.44 million in the previous year[20]. - The company achieved operating revenue of 1,193.57 million RMB in 2024, a year-on-year increase of 17.70%[34]. - The net profit attributable to the parent company was 704.58 million RMB, representing a year-on-year growth of 139.15%[34]. - The company recognized a one-time special dividend from its associate Numab amounting to RMB 41,080.10 million, significantly contributing to the profit growth in 2024[26]. - The gross margin improved to 65%, up from 60% in the previous year, due to cost optimization strategies[15]. - The company reported a revenue of 990.904 million RMB from biopharmaceuticals, with a gross margin of 80.05%, representing a year-on-year increase of 17.74% in revenue and a 9.26% increase in cost[150]. Research and Development - The company faces significant risks in innovative drug development, including long R&D cycles, high investment, and low success rates, which could adversely affect future product launches and market competitiveness[3]. - Increased R&D expenditures are anticipated due to the deepening of ongoing projects, which may lead to losses if R&D costs exceed profits from commercialized products[4]. - The company's R&D expenditure as a percentage of operating revenue increased by 14.31 percentage points to 45.29%, driven by a rise in the number of major R&D projects[21]. - The company has 22 ongoing autoimmune projects, an increase of 8 from the previous year, with 1 NDA review stage project and 5 clinical phase III projects[46]. - The company’s clinical trial projects from China now account for 28% of the global total, up from 3% a decade ago[32]. - The company has multiple projects entering Phase III clinical trials, including four key projects with a total expected investment of ¥202,569.52 million[93]. - The company’s R&D expenditure capitalization ratio is 34.06%[154]. - The company has established a comprehensive R&D platform covering drug development from basic research to new drug registration[66]. Market and Competitive Landscape - The company is expanding its market presence in Southeast Asia, with plans to enter three new countries by Q3 2024[15]. - The market penetration rate for autoimmune biological agents remains low, indicating significant growth potential in the sector[33]. - The company’s product Yisaipu is facing increasing competition with over 10 new brands entering the market, leading to price declines and ongoing procurement risks[81]. - The company is adapting to the challenges posed by centralized drug procurement reforms, which are reshaping the pharmaceutical industry landscape[78]. - The global market for targeted biological agents has replaced small molecule drugs as the primary treatment for autoimmune and inflammatory diseases[73]. - The company is focusing on developing bispecific antibodies, which can target multiple signaling pathways for more effective treatments[86]. Corporate Governance - The company has not yet achieved profitability since its listing, indicating ongoing financial challenges[3]. - There are no significant non-operating fund occupations by controlling shareholders or related parties, indicating sound corporate governance[8]. - The company has not implemented any special arrangements for corporate governance, maintaining standard practices[8]. - The company adheres to strict corporate governance practices, ensuring compliance with relevant laws and regulations while maintaining transparency and accountability to shareholders[174]. Strategic Initiatives - The company plans to distribute a cash dividend of RMB 0.90 per 10 shares, totaling approximately RMB 55.51 million, which represents 7.88% of the net profit attributable to ordinary shareholders[6]. - The company plans to increase its marketing budget by 15% to support new product launches and market expansion efforts[15]. - A strategic acquisition of a biotech firm was announced, expected to enhance the company's R&D capabilities and add 150 million RMB in annual revenue[15]. - The company is investing 200 million RMB in new technology development to improve drug delivery systems[15]. - The company aims to enhance its competitive edge by focusing on the industrialization and clinical application of antibody drugs for autoimmune diseases[88]. Human Resources and Leadership - The company has a dedicated sales team of nearly 300 professionals, with an average industry experience of over 10 years among core sales personnel[69]. - The management team has an average of over 20 years of experience in the pharmaceutical industry, with the chairman having led the development of several national class I new drugs[101]. - The company has implemented long-term incentive mechanisms, including talent retention rewards and employee stock ownership plans, to mitigate the risk of key personnel turnover[110]. - The company is committed to developing a diverse talent incentive mechanism to attract and retain innovative research talent in the competitive biopharmaceutical industry[172]. Financial Management - The net cash flow from operating activities decreased by 32.48% to RMB 28,113.60 million, down from RMB 41,635.40 million in 2023, primarily due to increased costs associated with product sales and R&D projects[22]. - The company reported a net cash outflow of 52.374 million RMB for financing activities in 2024, primarily for dividends and interest repayments[119]. - The company’s long-term equity investment decreased by 56.17% to 38.6708 million RMB due to continuous losses from the associate Numab[137]. - The company has established a remuneration scheme for directors and senior management, which is subject to approval by the board and the compensation committee[193].

Investment Rating - The report assigns a rating of "Accumulate" for the company [4]. Core Views - The company has shown significant growth in profits, with total revenue for 2024 reaching 1.194 billion yuan, a year-on-year increase of 17.70%, and a net profit attributable to shareholders of 732 million yuan, up 148.34% year-on-year [1][2]. - The sales revenue of the company's main products has steadily increased, with a 17.74% year-on-year growth in product sales revenue for 2024. The growth is attributed to the robust sales of Yisaipu and the rapid expansion of Yisaipu pre-filled syringe types, which effectively compensated for the decline in product average prices due to regional centralized procurement [2]. - The company is focusing on research and development, with total R&D investment of 354 million yuan in the first three quarters of 2024, a year-on-year increase of 54.07%. The R&D expense ratio remains at a reasonable level, with several key pipelines progressing steadily [3]. Financial Projections - The company is expected to achieve revenues of 1.459 billion yuan and 1.754 billion yuan in 2025 and 2026, respectively, with net profits attributable to shareholders projected at 396 million yuan and 486 million yuan for the same years. The earnings per share (EPS) are forecasted to be 0.64 yuan and 0.79 yuan [3][7].

证券代码：688336 证券简称：三生国健 公告编号：2025-008 三生国健药业（上海）股份有限公司 2025 年第一次临时股东大会决议公告 本公司董事会及全体董事保证公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 重要内容提示： | 1、出席会议的股东和代理人人数 | 100 | | --- | --- | | 普通股股东人数 | 100 | | 2、出席会议的股东所持有的表决权数量 | 12,188,688 | | 普通股股东所持有表决权数量 | 12,188,688 | | 3、出席会议的股东所持有表决权数量占公司表决 | 1.9761 | 本次会议是否有被否决议案：无 一、 会议召开和出席情况 （一） 股东大会召开的时间：2025 年 3 月 7 日 （二） 股东大会召开的地点：中国（上海）自由贸易试验区李冰 路 399 号公司会议室 （三） 出席会议的普通股股东、特别表决权股东、恢复表决权的 优先股股东及其持有表决权数量的情况： | 权数量的比例（%） | | | --- | --- | | 普通股股东所持有表决权数量占公司表决权数量 ...